# US 2024/0383909 A1 · Co-crystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0383909 A1
- Document ID: US20240383909A1
- Status: Published application
- Kind: A1
- Application number: 18/688,618
- Filed: 2022-09-02
- Published: 2024-11-21
- Earliest claimed: 2021-09-03
- Applicants: Intra-Cellular Therapies, Inc.
- Inventors: Peng LI
- Web page: https://patentgrep.com/patent/US20240383909A1

## CPC

- C07D 487/14: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07C 39/08: Dihydroxy benzenes; Alkylated derivatives thereof
- C07C 215/12: the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to co-crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, compositions comprising the same, as well as methods of making and using such co-crystals.

## Claims

### Claim 1

A co-crystal comprising:
A) (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free, pharmaceutically acceptable salt or prodrug form, including its enantiomers, diastereoisomers and racemates; and
B) a co-crystal former.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The co-crystal according to claim 1, wherein Compound 1 is in free base form.

### Claim 4 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal is anhydrous or solvated.

### Claim 5 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal former is selected from alanine, glutamic acid, 2-aminobutyric acid, urea, tyrosine, glycine, arginine, 6-hydroxy nicotinamide, diethanolamine, 3-nitro-phthalimide, isoleucine, histidine, bis acetyled ethylenediamide, nicotinamide, acetanilide, leucine, lysine, isonicotinamide, resorcinol, 4-nitro phthalimide, proline, serine, pyridino phthalimide, 4-acetamidophenol Benzamide, valine, threonine, tromethamine, hydroquinone, carbamazepine, phenylalanine, cysteine, 3-aminobutyric acid, piperazine, 4-acetamidophenol, tryptophan, methionine, 6-methylpyridine-3-carboxamide, succinimide, aspartic acid, asparagine, mono acetyled ethylenediamine, 4-methylacetanilide, glutamine, 2-pyridone, pyromellitic diimide, 1,2-dihydroxybenzene, amino-4,6-dimethyl nicotinamide, and salts thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal former is 3-nitro-phthalimide.

### Claim 9 (depends on 8)

The co-crystal according to claim 8, wherein the co-crystal exhibits an X-ray powder diffraction pattern comprising at least five peaks having 2-theta angle values selected from the group consisting of: 7.8, 16.3, 17.0, 17.4, 18.6, 19.1, 19.6, 20.8, 21.4, and 21.5 degrees, wherein the XRPD pattern is measured in a diffractometer using copper anode, e.g., at wavelength alpha1 of 1.5406 Å and wavelength alpha2 of 1.5444 Å.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 8)

The co-crystal according to claim 8, wherein said co-crystal exhibits a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 110° C.-111° C., e.g., about 110.5° C.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal former is diethanolamine.

### Claim 16 (depends on 15)

The co-crystal according to claim 15, wherein the co-crystal exhibits an X-ray powder diffraction pattern comprising at least five peaks having 2-theta angle values selected from the group consisting of: 7.29, 7.70, 7.80, 9.987, 13.78, 16.59, 16.93, 18.84, 20.66, and 20.68 degrees, wherein the XRPD pattern is measured in a diffractometer using copper anode, e.g., at wavelength alpha1 of 1.5406 Å and wavelength alpha2 of 1.5444 Å.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 15)

The co-crystal according to claim 15, wherein said co-crystal exhibits a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 121° C.-122° C., e.g., about 121.7° C.

### Claim 21 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal former is resorcinol.

### Claim 22 (depends on 21)

The co-crystal according to claim 21, wherein the co-crystal exhibits an X-ray powder diffraction pattern comprising at least five peaks having 2-theta angle values selected from the group consisting of: 7.3, 7.4, 10.0, 14.1, 17.0, 18.7, 19.0, 19.7, 22.9, and 23.7 degrees, wherein the XRPD pattern is measured in a diffractometer using copper anode, e.g., at wavelength alpha1 of 1.5406 Å and wavelength alpha2 of 1.5444 Å.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 21)

The co-crystal according to claim 21, wherein said co-crystal exhibits a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 160° C.-162° C., e.g., about 161° C., and about 167° C.-168° C., e.g., about 167.4° C.

### Claim 27 (depends on 1)

The co-crystal according to claim 1, wherein the co-crystal former is hydroquinone.

### Claim 28 (depends on 27)

The co-crystal according to claim 27, wherein the co-crystal exhibits an X-ray powder diffraction pattern comprising at least five peaks having 2-theta angle values selected from the group consisting of: 7.26, 7.42, 9.94, 17.21, 18.41, 18.38, 19.44, 19.47, 23.08, and 23.73 degrees, wherein the XRPD pattern is measured in a diffractometer using copper anode, e.g., at wavelength alpha1 of 1.5406 Å and wavelength alpha2 of 1.5444 Å.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 27)

The co-crystal according to claim 27, wherein said co-crystal exhibits a Differential Scanning calorimetry (DSC) pattern comprising an endothermic peak at about 209° C.-210° C., e.g., about 209.2° C.

### Claim 33

(canceled)

### Claim 34

A process for the production of a co-crystal comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free, pharmaceutically acceptable salt or prodrug form, including its enantiomers, diastereoisomers and racemates; and a co-crystal former, the method comprising the steps of reacting Compound 1 with the co-crystal former and isolating the obtained co-crystal.

### Claim 35 (depends on 34)

The process according to claim 34, further comprising the step of dissolving Compound 1 in a first solvent comprising an alcohol and/or water.

### Claim 36

(canceled)

### Claim 37 (depends on 34)

The process according to claim 34, further comprising the step of dissolving the co-crystal former in a second solvent.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The process according to claim 37, further comprising mixing the resultant solution comprising Compound 1 in the first solvent with the resultant solution comprising the co-crystal former and the second solvent.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)
